142 results about "Type antigen" patented technology

The invention discloses an antibody for resisting HPV16 and / or HPV18 type E2 protein and application of the antibody, and relates to the technical field of biological medicine. The antibody comprises a heavy chain complementarity determining region in a heavy chain variable region as shown in SEQ ID NO: 1 and a light chain complementarity determining region in a light chain variable region as shown in SEQ ID NO: 2. The antibody can be specifically combined with HPV16 and / or HPV18 type E2 protein. Based on the antibody provided by the invention, a reagent, a kit, a test strip, an antibody chip, an antibody probe or a detector for detecting the HPV16 and / or HPV18 type E2 antigen can be developed. Tests show that a kit developed based on the monoclonal antibody has the advantages of high detection sensitivity, good specificity / specificity, high precision, high accuracy, fast detection and strong tolerance, and can be used for quality control in the production process of recombinant human HPV16 and / or HPV18 type E2 antigens.

The invention discloses a GPC3 derived antigen peptide vaccine, an mRNA vaccine, a saRNA vaccine and a preparation method and application thereof. The amino acid sequence of the antigen peptide vaccine is one or any combination of more of amino acid sequences shown as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6. According to the invention, an efficient pGPC3 model antigen peptide is screened on the basis of GPC protein, and pGPC3 mRNA and pGPC3 saRNA are designed according to a pGPC3 sequence example. The pGPC3saRNA (at) Lipi vaccine is prepared through a liposome technology, and due to the fact that limiting conditions such as nonapeptide and high-affinity binding with H-2I type molecules (H-2Kb) are adopted during pGPC3 polypeptide antigen screening, APC cells are facilitated to present antigens through an MHCI restrictive pathway, CD8 + T cells are activated, and GPC3 specific CTL is triggered to efficiently kill liver cancer cells. Finally, the pGPC3saRNA (at) Lipi vaccine can completely inhibit the growth of the liver cancer, the inhibition rate reaches 99.8%, and the liver cancer of 4 / 8 mice completely fades down. In addition, the method can be used for vaccine adjuvant and carrier research on a liver cancer subcutaneous transplantation tumor model.

The invention discloses an antibody for resisting HPV16 and / or HPV18 type E2 protein, an antibody conjugate and application of the antibody conjugate, and relates to the technical field of medical biology. The antibody comprises a heavy chain complementarity determining region in a heavy chain variable region as shown in SEQ ID NO: 1, and a light chain complementarity determining region in a light chain variable region as shown in SEQ ID NO: 2. Tests show that a kit developed based on the monoclonal antibody has the advantages of high detection sensitivity, good specificity, high intermediate precision, high accuracy, consistent linear range of standard curves, fast detection and strong tolerance for the HPV16 and / or HPV18 type E2 antigen, can be used for quality control in the production process of the recombinant human HPV16 and / or HPV18 type E2 antigen, and has wide application prospects. The antigen content in the vaccine can be efficiently and accurately quantified, and the quality of the vaccine can be monitored.

The invention discloses a preparation method of an oxidized low-density lipoprotein quality control product prepared on the basis of a novel antigen, and the method comprises the following steps: constructing an oxidized low-density lipoprotein model, carrying out molecular dynamics simulation by setting a plurality of groups of simulation conditions to calculate a stability index, and determining an optimal antigen preparation condition; acquiring antigen epitope data, and constructing a feature vector, so as to predict and screen an optimal antigen epitope by utilizing a machine learning algorithm; and based on a target cross-linking strategy, combining the oxidized low-density lipoprotein prepared under the optimal antigen preparation condition with the optimal epitope to obtain a target quality control product. According to the scheme, the preparation efficiency and quality can be improved.

The present disclosure provides lipid nanoparticle compositions comprising a nucleic acid encoding an RSV antigenic polypeptide. The invention also provides novel antigenic RSV-F polypeptides as well as nucleic acids encoding the antigenic RSV-F polypeptides.

The invention belongs to the field of biology, and discloses a foot-and-mouth disease virus O-type inner broad-spectrum neutralizing swine monoclonal antibody and application thereof, the amino acid sequence of a heavy chain variable region of the monoclonal antibody is shown as SEQ ID NO.1, the amino acid sequence of a light chain variable region of the monoclonal antibody is shown as SEQ ID NO.2, the antigen key amino acid residue recognized by the monoclonal antibody is VP2 protein 77 site, and the amino acid sequence of the heavy chain variable region of the monoclonal antibody is shown as SEQ ID NO.1. The amino acid sequence of the light chain variable region of the monoclonal antibody is shown as SEQ ID NO.2. The site is located at a structural protein VP2B-C ring, is a conformational epitope, does not react with an A-type antigen, is an intra-strain broad-spectrum neutralizing antibody, and shows relatively strong neutralizing efficacy (IC50 is less than 5 [mu] g.mL <-1 >). Meanwhile, the invention also provides application of the monoclonal antibody.

The invention relates to the technical field of vaccines, and discloses a preparation method and application of an anti-tumor vaccine based on an autoantigen and a synthetic antigen. The anti-tumor vaccine comprises a tumor autoantigen and a synthetic antigen, wherein the tumor autoantigen is extracted from a tumor cell membrane, a tumor cell lysate, a tumor cell secretion, an exosome antigen or an antigen released by a tumor microenvironment; the synthetic antigen is selected from at least one of a tumor associated antigen, a tumor specific antigen, a personalized neoantigen, a pathogen antigen, a biotoxin, a biomolecule antigen and coding nucleic acid of a peptide type antigen in the antigens; the coding nucleic acid is DNA or mRNA. The vaccine molecule composed of the tumor autoantigen and the synthetic antigen is easy to prepare, has a strong anti-tumor immune effect and good biological safety, solves the problems that the traditional tumor autoantigen has no specific precise target spot and the synthetic antigen is single in immunogen, and has a wide application prospect.

The present invention relates to an antigen for egg allergy. The present invention provides a novel antigen for egg allergy, a diagnostic method and a diagnostic kit for egg allergy, a pharmaceutical composition containing the antigen, an egg or egg processed product with the antigen removed or reduced, or a bird producing the egg or hatched from the egg, or a method for producing an egg processed product with the antigen removed or reduced, and a detector for determining whether an object has an egg antigen.

The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.

The invention relates to the technical field of vaccines, in particular to an activity detection method of an HPV (human papilloma virus) trivalent therapeutic vaccine. The method comprises the following steps: inoculating and infecting BEAS-2B cells by adopting constructed HPV16 / 18 / 52 type E6 / E7 antigen-loaded non-replicating type 5 adenovirus, culturing, extracting total protein, sequentially performing SDS-PAGE (Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis), western blot detection, immunoreaction and developing imaging, and detecting the fusion protein; the transfection complex number MOI of the constructed adenovirus is 15-25, and the convergence degree of BEAS-2B cells is greater than 80%; the membrane transfer current of the western blot method is 220-280 mA, and the time is 50-80 minutes. The method avoids the problem of inaccurate detection results caused by obvious difference of biological activities in different animal species, has good accuracy, stability and durability, is simple in steps and low in cost, and can be effectively popularized and used.

The invention provides preparation of a novel O antigen and specific serum of vibrio parahaemolyticus. The classification name of the vibrio parahaemolyticus is vibrio parahaemolyticus O17: K4, and the preservation number of the vibrio parahaemolyticus O17: K4 is CGMCC (China General Microbiological Culture Collection Center) No.31706. The invention further discloses a preparation method of the vibrio The novel thallus antigen O17 vibrio parahaemolyticus is determined by adopting an agglutination reaction and a whole genome sequencing method of existing diagnostic serum (11 kinds of O) of the vibrio parahaemolyticus. The novel O17 specific serum is obtained through preparation of a novel thallus antigen O17, animal immunization and adsorption separation. The novel O17 specific serum prepared by the invention is high in sensitivity and strong in specificity, can be conveniently and quickly used for detecting a brand new novel thallus antigen O17 vibrio parahaemolyticus which is prevalent in recent years, and provides an important detection technology for pathogen confirmation, monitoring and prevention and control of infectious diarrhea and food-borne diseases in laboratories.

The invention belongs to the technical field of biological medicines, and particularly relates to an MAF vaccine as well as a preparation method and application thereof. In order to develop a nasal spray type vaccine capable of effectively preventing and treating fibrotic interstitial lung diseases and avoiding risk increase caused by local inflammatory reaction, the invention adopts two modes of taking a synthesized MAF protein as a model antigen, encapsulating the MAF protein by using a TLR7 adjuvant to form a peptide fragment vaccine or constructing an MAF adenovirus vaccine based on an adenovirus vector. Two vaccines based on the MAF target spot are successfully constructed. Animal experiment results prove that the two vaccines based on the MAF target spot have treatment and prevention effects on bleomycin-induced mouse pulmonary fibrosis models during nasal dripping immunization, and also have good safety in vivo. A good candidate vaccine is provided for future fibrotic disease prevention and treatment vaccine transformation research and clinical experiment development.

The present invention relates to bi-specific antigen binding molecules with specificity for both receptor tyrosine kinase-like orphan receptor 1 (ROR1) and epidermal growth factor receptor (EGFR) and associated fusion proteins and conjugates. In a further aspect, the present invention relates to conjugated immunoglobulin-like shark variable novel antigen receptors (VNARs).

The present application provides enhanced APCs for use in the treatment of HPV-associated cancers. The enhanced APC is capable of activating T cells in an HLA-agnostic manner and is derived from an input APC in which at least one nucleic acid encoding an HPV antigen has been delivered within the cell. In some aspects, the enhanced APC is administered in combination with an immune checkpoint inhibitor, such as an antagonist of PD-1 / PD-L1 and / or an antagonist of CTLA-4.

The invention relates to the field of biological detection, in particular to a broad-spectrum specific antibody and application thereof. The invention provides a monoclonal antibody of human immunodeficiency virus P24 protein. Three CDR regions of a heavy chain of the monoclonal antibody respectively have amino acid sequences shown as SEQ ID NO: 3, 4 and 5; the three CDR regions of the light chain of the gene respectively have amino acid sequences as shown in SEQ ID NO: 7, 8 and 9. A recombinant human immunodeficiency virus P24 protein is used as an immunogen, a monoclonal antibody capable of simultaneously detecting HIV-1 and HIV-2 core proteins P24 is successfully prepared through different multi-type antigen sequential immunization strategies, an epitope interval of the monoclonal antibody is determined through a recombinant P24 fragment, and a foundation is laid for establishing a detection kit with higher sensitivity.

The present invention discloses an antibody against HPV16 and / or HPV18 type E2 protein, an antibody conjugate and their applications, which relate to the field of medical biotechnology. The antibody comprises the heavy chain complementarity determining regions in the heavy chain variable region shown in SEQ ID NO: 1, and the light chain complementarity determining regions in the light chain variable region shown in SEQ ID NO: 2. After testing, the kit developed based on this monoclonal antibody has the advantages of high detection sensitivity for HPV16 and / or HPV18 type E2 antigen, good specificity, high intermediate precision, high accuracy, consistent linear range of the standard curve, rapid detection and strong tolerance. It can be used for quality control in the production process of recombinant human HPV16 and / or HPV18 type E2 antigen, can efficiently and accurately quantify the antigen content in the vaccine, and monitor the vaccine quality.

According to the kit for detecting the helicobacter pylori CagA subtype and the application of the kit, 3E67 and 5T68 monoclonal antibodies are prepared by using CagA dominant immune epitopes, and the monoclonal antibodies are used in a homogeneous chemiluminescence system for the first time to prepare an antigen for detecting the helicobacter pylori CagA subtype. A murine antibody is prepared through immunization of dominant epitopes of helicobacter pylori CagA protein, an antibody pair with good specificity and strong binding force is obtained through an in-vitro screening pairing strategy, and amino acid sequences of a heavy chain variable region and a light chain variable region of the antibody pair are obtained through sequencing. Products for detecting the helicobacter pylori-related CagA antigen are developed on the basis of a chemiluminescence platform, an enzyme-linked immunosorbent assay platform and an immune layer system platform, and the kit has the advantages of high sensitivity, good specificity and rapid detection.

The present invention generally relates to improved protease-activatable antigen-binding molecules. The protease-activatable antigen-binding molecules contain an anti-idiotypic binding portion that reversibly masks the CD3 antigen-binding portion of the molecule. Furthermore, the present invention relates to polynucleotides encoding such protease-activatable T cell binding molecules, as well as vectors and host cells containing such polynucleotides. The present invention further relates to methods for producing the protease-activatable T cell binding molecules of the present invention and methods for using the protease-activatable T cell binding molecules, for example, in the treatment of diseases.

Provided is a low mass antigen detecting device for quickly and conveniently detecting various types of antigens. In a low mass antigen detecting device for detecting a low mass antigen through a sensor, the sensor includes a piezo-electric substrate, a sensing layer coupled to one surface of the piezo electric substrate and comprising at least one antigen-BSA, an input IDT electrode disposed at one side of the piezo-electric substrate to apply an input frequency provided as a sweep frequency, and an output IDT electrode disposed at the other side of the piezo-electric substrate to output an output frequency.

The invention relates to a multi-metal element nano-aluminum adjuvant and a preparation method and application thereof, the nano-aluminum adjuvant is a nano-particle containing an aluminum element and at least one metal element selected from magnesium, zinc and calcium, the nano-particle has a layered crystal structure, and the particle size is distributed in a range of 20-2000 nm. The difunctional nano-aluminum adjuvant has the beneficial effects that the difunctional nano-aluminum adjuvant is simple and convenient in preparation method, definite in component and uniform in particle size, the particle size of the particles can be manually regulated and controlled, and the difunctional nano-aluminum adjuvant can directly promote antigen presenting cells to be mature and activated and carry out MHC-I or II type antigen presentation.

The invention belongs to the field of biology, and discloses a broad-spectrum neutralizing porcine monoclonal antibody for foot-and-mouth disease virus type O and its application. The amino acid sequence of the heavy chain variable region of the monoclonal antibody is shown in SEQ ID NO.1, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.2. The key amino acid residue of the antigen recognized by the monoclonal antibody is position 77 of the VP2 protein. The site is located in the VP2B-C loop of the structural protein and is a conformational epitope. The site does not react with type A antigen, is a broad-spectrum neutralizing antibody within the type, and exhibits a strong neutralizing efficacy (IC 50 <5μg·mL ‑1 ). At the same time, the present invention also provides the application of the monoclonal antibody.

The present application relates to the field of medicine, and specifically discloses a nine-valent human papillomavirus vaccine and its application. The nine-valent human papillomavirus vaccine includes truncated L1-VLP antigens of HPV6, 11, 16, 18, 31, 33, 45, 52, and 58, and an aluminum hydroxide adjuvant. The antigen components in the nine-valent HPV vaccine provided by the present invention are all derived from the main capsid protein L1 of HPV and are truncated. The truncated L1 protein expressed by the Escherichia coli system increases the yield of the L1 protein and reduces the production cost of the vaccine. The present application optimizes the particle size of each type of VLP antigen and the particle size of the aluminum hydroxide adjuvant, and controls the ratio of each type of VLP antigen and the aluminum hydroxide adjuvant, so that the obtained nine-valent HPV vaccine induces a high level of immune response, especially showing obvious effects in clinical practice, which is better than the effects of related vaccines currently on the market.

The application provides a PLA2R monoclonal antibody and an ELISA kit comprising the antibody. Specifically, the application provides a monoclonal antibody which specifically binds to PLA2R, wherein the antibody only binds to non-reduced PLA2R antigen with a conformational epitope, does not bind to reduced PLA2R antigen, and does not bind to another antigen THSD7A of primary membranous nephropathy. An ELISA kit prepared based on the antibody can more efficiently and accurately detect primary membranous nephropathy than existing commercial kits.

The present invention provides protected tetrasaccharides, their process of preparation and their use as common scaffold precursors in the synthesis of oligosaccharides representing segments of the O-antigens from diverse S. flexneri serotypes, comprising for example SF2a, SF3a, SF2b, SF1b, SFX and / or SFY.

The application provides novel peptide epitope tags and recombinant polynucleotide, polypeptides, vectors, cells and compositions comprising the tags. The application also provides novel designs for synthetic antigen receptors (SARs), novel antigen binding domains, novel SAR constructs and novel methods for manufacturing of cell therapy products. These novel methods and compositions have broad uses in cellular therapy.

The application provides an anti-Norovirus GII genotype VP1 antigen monoclonal antibody and an application thereof. The anti-Norovirus GII genotype VP1 antigen monoclonal antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises a heavy chain CDR3 shown in SEQ ID NO. 3, and the light chain variable region comprises a light chain CDR3 shown in SEQ ID NO. 6. The monoclonal antibody is a rabbit-derived monoclonal antibody, the monoclonal antibody has good specificity and high affinity, and solves the problem of a mouse-derived monoclonal antibody in actual application. The anti-Norovirus GII genotype VP1 antigen monoclonal antibody has important application value in the preparation of a product for detecting Norovirus.

To provide vaccine platforms that enhance biological response to viral, bacterial, or tumor antigens.SOLUTION: The present invention provides a vaccine comprising a fusion protein containing an interferon-target antigen-immunoglobulin Fc region (or antibody) and a Th cell helper epitope. The present invention also relates to the use of a fusion protein containing an interferon-target antigen-immunoglobulin Fc region (or antibody) and a Th cell helper epitope for preparing a preventive or therapeutic composition. The vaccine of the present invention is produced by a eukaryotic cell expression system, and wild-type and various mutant antigen vaccines can be prepared, and a strong immune response can be induced in the living body by inoculation via an immune route such as subcutaneous / muscle or nasal cavity. The vaccine of the present invention can be used as a preventive or therapeutic vaccine.SELECTED DRAWING: None

Provided is a novel antigen detection method capable of detecting an antigen, as a substance to be detected, by using a signal transmission line for transmitting a high-frequency signal. This antigen detection method for detecting an antigen in a sample comprises: a step in which a sample, containing an antigen reacted with both a primary antibody for fixing the antigen to a carrier and a secondary antibody labelled with magnetic particles, is produced; a step in which the sample is placed close to or in contact with a probe in which a signal transmission line is formed; a step in which a DC magnetic field in a direction along the signal transmission line is applied to the sample by a magnetic field application means; a step in which a high-frequency signal is supplied to the signal transmission line by a signal measurement instrument electrically connected to the signal transmission line; a step in which a signal being transmitted along the signal transmission line in a state in which the DC magnetic field is being applied is measured by the signal measurement instrument over a predetermined frequency band; and a step in which the antigen is detected by an arithmetic processing means on the basis of a signal corresponding to the resonance frequency of ferromagnetic resonance observed in the predetermined frequency band.

The invention discloses an FUT2 high-expression cell strain as well as application and a method of the FUT2 high-expression cell strain in vaccine quality control, and belongs to the technical field of vaccines. The technical problem to be solved is that a simple and easy-to-operate cell model is lacked in the prior art, and the cell model is used for evaluating the effectiveness of NoV vaccines on the cellular level. According to the key points of the technical scheme, the FUT2 high-expression cell strain is provided, the cell strain is an HEK 293T cell strain (HEK 293T-FUT2-EGFP) with EGFP fluorescence for overexpressing human alpha 1, 2-fucosyltransferase 2 (FUT2), and the cell strain stably expresses H, Lewis b and Lewis y type HBGA antigens; meanwhile, an alternative neutralization experiment of the cell level of the norovirus vaccine based on the cell strain is developed, a basis is provided for interaction research of the norovirus and host cells, and the cell strain has high practical application value.

Disclosed is a chemical synthesis method for Pseudomonas aeruginosa O5 serotype O-antigen oligosaccharide, which belongs to the field of chemical synthesis. In the disclosure, O-antigen trisaccharide is constructed with a D-glucuronic acid building block and a D-fucosamine building block, where the stereoselective synthesis of a 1,2-α-cis-glycosidic bond of D-fucosamine depends on remote acyl participation and reagent regulation, and synthesis of two types of 1,2-β-trans-glycosidic bonds of 2,3-diaminomannuronic acids is achieved via SN2 nucleophilic substitution of azido at position C2; and via selective assembly of protecting groups, orthogonal modification of modifying groups, and regulation of the reactivity of glycosyl donors and acceptors, multifunctional modified O-antigen target trisaccharide is successfully prepared. According to the method in the disclosure, the raw materials are cheap and easily available, and the preparation method is simple and easy to repeat. Therefore, the method has a very good application prospect in developing vaccines against P. aeruginosa.